<p>Vaso Corporation announced that its wholly owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, has signed an amendment to its sales representation agreement with GE HealthCare to extend the term of the agreement through December 31, 2030. This marks the fifth extension of the agreement, which originally began in May 2010. Under the amended terms, VasoHealthcare will continue to represent GE HealthCare’s portfolio of diagnostic imaging and ultrasound products and services, including CT, MR, molecular imaging, X-ray, mammography, and interventional guided solutions systems, as well as associated service and financial offerings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaso Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603425-en) on December 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

GEHC

<p>Vaso Corporation Extends Sales Agreement with GE HealthCare Through 2030</p>